Clinical Trial Search

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Response Rate — .125 proportion of participants

Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001

Primary: Overall Survival (OS) — 9.38; 14.7 Months

Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants

Primary: Overall Survival — 24.8 Months

Primary: Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90…

Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001

Primary: Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the…

Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months

Primary: Six-Month Participant Survival — 7 Participants

Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants

Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 1 participants

Primary: Change in Serum Adiponectin Level — 34.47; 29.77 μg/ml

Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…

Primary: Safety of Combining the Pancreatic Tumor Vaccine in Sequence With Cyclophosphamide and Erbitux. Safety is Defined as the Number of Treatment-related Grade 3 or 4 Adverse…

Primary: Number of Participants With Adverse Events — 3; 4; 10; 2 participants

Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants

Primary: Progression-free Survival — 5.7 months

Primary: Number of Participants With Progressive Disease, — 2 Participants

Primary: Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy — 49 percent of patients

Primary: Dose Limiting Toxicities — 0; 0; 1; 3 Participants

Primary: Progression-free Survival — 3.9 months

Primary: Phase 1b: Recommended Phase 2 Dose — 300 milligrams (mg)

Primary: Median Overall Survival (OS) — 42 months

Primary: Number of Participants With Resectability Rate — 15 Participants

Primary: Local Control Rate — 1 Participants

Primary: Time to Tumor Progression — 3.5 months

Primary: Survival — 37; 31 participants